$15.330
-0.428 (-2.79%)收盤時
GENB 資訊
GENB 事件
Generate Biomedicines Stock Falls 16.7% to $16.97
Generate Biomedicines is down -16.7%, or -$3.41 to $16.97.
Generate Biomedicines Stock Falls 11% to $18.13
Generate Biomedicines is down -11.0%, or -$2.25 to $18.13.
Generate Biomedicines Stock Rises 17.7% to $20.86
Generate Biomedicines is up 17.7%, or $3.14 to $20.86.
Generate Biomedicines Stock Falls 9.5% to $14.22
Generate Biomedicines is down -9.5%, or -$1.50 to $14.22.
Generate Biomedicines Advances Multiple Clinical Trials
"We saw strong progress in the first quarter across our clinical pipeline, next generation of therapeutic programs, and advancing our platform," said Mike Nally, chief executive officer of Generate Biomedicines, Inc. "We are advancing GB-0895 in Phase 3 for severe asthma and Phase 1b for COPD. In oncology, we expect to progress two clinical trials this year with GB-4362, an MMAE neutralizer, and GB-5267, a MUC16 CAR T developed with Roswell Park. Together, these programs reflect the breadth of our clinical portfolio across therapeutic areas, modalities, and both wholly owned and partnered programs."
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。